Core Insights - Defence Therapeutics Inc. has established its inaugural Scientific Advisory Board (SAB) to enhance its Accum®-Antibody drug conjugate (ADC) program, which has shown significant laboratory validation results [2][3][9] Group 1: Scientific Advisory Board Formation - The SAB consists of experts Rob Leanna, Danny Chui, and Brendan Hussey, who will provide scientific, technical, and strategic guidance for the company's programs [2][4] - The formation of the SAB aims to strengthen Defence's scientific foundation and support disciplined decision-making as the company advances its Accum® platform [9] Group 2: Accum®-Antibody Drug Conjugate Program - Defence's Accum®-ADC program has achieved laboratory validations, indicating a notable increase in intracellular accumulation and improved efficacy [3] - The SAB will help shape the direction and scientific priorities of the Accum®-enabled ADC programs as they progress towards clinical development [3][9] Group 3: Expertise of SAB Members - Rob Leanna brings extensive experience in ADC and drug-linker chemistry, having previously led development and regulatory strategy at AbbVie Inc. [5] - Danny Chui has over 20 years of experience in therapeutic antibody discovery and ADC development, contributing expertise in antibody engineering and preclinical pharmacology [6] - Brendan Hussey, with a background in biotechnology and investment banking, will align Defence's platform with market opportunities and partner expectations [7] Group 4: Company Overview - Defence Therapeutics is focused on engineering next-generation ADC products using its proprietary Accum® technology, which enhances the precision delivery of biologics [10] - The Accum® platform aims to improve efficacy and potency for biologics, thereby expanding patient access and market opportunities [10]